A "misfire" is the way Eric Topol, MD, describes 23andMe's recent regulatory tussle with the FDA, which resulted in the Silicon Valley-based company halting sales for now of its health-related genetic test analysis. Speaking with MPMN ...
Tags: 23andme, FDA, regulatory tussle